Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
12/2002
12/18/2002CN1386132A Antimicrobial composition
12/18/2002CN1096279C Foaming mixture of alkalis salt or lysine salt with acid unresolvable or difficult resolving active material
12/18/2002CA2388761A1 Wound healing biomarkers
12/17/2002US6495669 Amphiphilic, polyhedron-shaped p-sulfonatocalix(4)arene building blocks, which have been shown previously to assemble into bilayers in an antiparallel fashion, assemble in a parallel alignment into spherical and helical tubular
12/17/2002US6495608 Methods of performing surgery with galactomannan polymers and borate
12/17/2002US6495585 Method for treating hyperproliferative tissue in a mammal
12/17/2002US6495582 Erk (extracellular signal regulated kinase) inhibitors for treatment of cancer, inflammatory disorders, restenosis, and cardiovascular disease
12/17/2002US6495573 Non-systemic control of parasites
12/17/2002US6495567 Triaryl methane compounds and their use in the treatment of diarrhea and scours
12/17/2002US6495560 10,11-dihydro-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-1 -ethoxy)-5h-dibenzo(a,d)cycloheptene-10-acetic acid; treatment of osteoporosis
12/17/2002US6495556 Treating leukemia and lymphoma, sunburn and skin cancer
12/17/2002US6495553 Methods and compositions for overcoming resistance to biologic and chemotherapy
12/17/2002US6495536 Fat or oil composition
12/17/2002US6495532 Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof
12/17/2002US6495530 Composition for treating a patient susceptible to or suffering from a cardiovascular disorder or disease
12/17/2002US6495376 Phosphoserine and phosphothreonine binding modules. the ww-domain containing polypeptides of the invention can be used, for example, to regulate cell growth; to treat neurodegenerative diseases; to screen for substances that
12/17/2002US6495359 Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor
12/17/2002US6495338 Drug screening and diagnosis based on paracrine tubular renin-angiotensin system
12/17/2002US6495330 Determining the level of p-type inositol phosphoglycans in a biological sample obtained from the patient, wherein said p-type ipgs are capable of activating pyruvate dehydrogenase phosphatase, by immunoassay
12/17/2002US6495171 Interleukin-4 production inhibitors
12/17/2002US6495158 Acne patch
12/17/2002US6495154 On demand administration of clomipramine and salts thereof to treat premature ejaculation
12/17/2002US6495147 Uses of D-xylose, the esters thereof and oligosaccharides containing xylose for improving the functionality of epidermal cells
12/17/2002CA2260311C Remedy for cag repeat expansion diseases
12/17/2002CA2250420C Combinations of vasopressin and adrenergic agents for the treatment of cardiac arrest
12/17/2002CA2246560C Methods of administering an ampa receptor antagonist to treat dyskinesias associated with dopamine agonist therapy
12/17/2002CA2225808C Silver-based pharmaceutical compositions
12/17/2002CA2204616C Ppar gamma antagonists for treating obesity
12/17/2002CA2148652C Substance p antagonist used in a cosmetic composition; composition thus produced
12/17/2002CA2108977C Luteinizing hormone releasing hormone antagonist peptides
12/17/2002CA2053826C Pharmaceutical compositions active in the therapy of neurological affections in aids patients
12/17/2002CA1341411C Method for producing fv fragments in eukaryotic cells
12/14/2002CA2390686A1 Cofactor-based screening method for nuclear receptor modulators and related modulators
12/12/2002WO2002099427A1 Srpks as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099426A1 Pecis as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099140A1 GLRAs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
12/12/2002WO2002099138A2 HS2STs AS MODIFIERS OF THE P53 PATHWAY AND METHODS OF USE
12/12/2002WO2002099125A1 PIBs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
12/12/2002WO2002099122A1 Modifiers of the p53 pathway and methods of use
12/12/2002WO2002099118A2 Method of identifying a polymorphism in cyp2d6
12/12/2002WO2002099115A2 Nucleic acid-associated proteins
12/12/2002WO2002099108A2 Atp-binding cassette transporter-like molecules and uses thereof
12/12/2002WO2002099090A1 Bcl-2 dnazymes
12/12/2002WO2002099083A2 Gfats as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099075A2 Prmts as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099074A2 Slc7s as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099068A2 Lces as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099060A2 Dgks as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099059A2 U5-200KDs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
12/12/2002WO2002099058A2 KCNMAs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
12/12/2002WO2002099057A2 Sams modifiers of the p53 pathway and methods of use
12/12/2002WO2002099056A2 C22c7orfs as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099055A2 Cips as modifiers of the p53 pathway and method of use
12/12/2002WO2002099054A2 Hccss as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099053A2 Slc22as as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099052A2 Opns as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099051A2 Nits as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099050A2 Tprs as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099049A2 Tbc1d1s as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099048A2 LIMKs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
12/12/2002WO2002099047A2 PROMLs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
12/12/2002WO2002099046A2 Spo11 as modifier of the p53 pathway and methods of use
12/12/2002WO2002099044A2 B3galts as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099043A2 P5CRS AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
12/12/2002WO2002099042A2 Cads as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099041A2 Ces2s as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099040A2 Igs as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099036A2 Inhibition of neurodegeneration
12/12/2002WO2002098920A1 Molecules and methods for inhibiting shedding of kim-1
12/12/2002WO2002098916A2 Transcriptional regulator of genes involved in the control of cell growth or cell proliferation. use of said regulator as a therapeutic or diagnostic agent
12/12/2002WO2002098907A2 Cation conducting gabaa receptors and their use
12/12/2002WO2002098899A2 CHDs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
12/12/2002WO2002098898A2 FLJs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
12/12/2002WO2002098891A2 GADs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
12/12/2002WO2002098890A2 MARKs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
12/12/2002WO2002098889A2 MAP3Ks AS MODIFIER OF THE p53 PATHWAY AND METHODS OF USE
12/12/2002WO2002098885A1 Modified psma ligands and uses related thereto
12/12/2002WO2002098515A2 Topical treatments using alkanolamines
12/12/2002WO2002098511A1 Compositions comprising oestrone-3-0-sulphamate and trail (tnf-related apoptosis inducing ligand)
12/12/2002WO2002098510A1 Combination of a ptpase inhibitor and an aldose reductase inhibitor
12/12/2002WO2002098501A2 Method and apparatus for treating tumors using low strength electric fields
12/12/2002WO2002098468A1 SLC13As AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
12/12/2002WO2002098467A1 Slc2as as modifiers of the p53 pathway and methods of use
12/12/2002WO2002098463A1 Antifungal compositions
12/12/2002WO2002098459A2 USE OF IgM ANTIBODIES AGAINST dsDNA IN SYSTEMIC LUPUS ERYTHEMATOSUS WITH NEPHRITIS
12/12/2002WO2002098458A1 Sphingosine kinase interacts with traf2 and modulates tumor necrosis factor-induced cellular activity
12/12/2002WO2002098444A2 Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis
12/12/2002WO2002098432A1 Methods of treating cardiac disorders
12/12/2002WO2002098431A1 Oxidant scavengers for treatment of diabetes or use in transplantation or induction of immune tolerance
12/12/2002WO2002098425A1 Substituted 4-aryl-3-(3-aryl-1-oxo-2-propenyl)-2(1h)-quinolinones and analogs as activators of caspases and inducers of apoptosis and the use thereof
12/12/2002WO2002098424A1 Novel anti-infectives
12/12/2002WO2002098422A1 Use of methylnaltrexone to treat immune suppression
12/12/2002WO2002098418A1 Combination comprising a p-gp inhibitor and an anti-epileptic drug
12/12/2002WO2002098416A2 Antineoplastic combinations
12/12/2002WO2002098413A2 Pharmaceutical compositions comprising orlistat and fatty acids and/or salts thereof
12/12/2002WO2002098411A1 Stabilizers of antioxidants and stabilizer-added antioxidant formulations and products
12/12/2002WO2002098410A1 Combination of a ptpase inhibitor and a sulfonylurea agent
12/12/2002WO2002098403A1 Steroid hormone and non-steroidal anti-inflammatory drug combinations for inducing tumor cell apoptosis
12/12/2002WO2002098402A1 Methods for the treatment of nail fungus and other microbial and mycotic conditions and compositions useful therefor
12/12/2002WO2002098391A2 Process for preparing granular compositions
1 ... 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 ... 1151